ar882
Small moleculeexperimental
Clinical trial activity
11 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Jan 22, 2019 (NCT04347005)
Timeline
Indications
Mechanism of action
- Uric acidBLOCKER
Uric acid blocker
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07116746 | Phase 2 | Sep 30, 2025 | Arthrosi Therapeutics |
| NCT06846515 | Phase 3 | Feb 28, 2025 | Arthrosi Therapeutics |
| NCT06439602 | Phase 3 | Jun 26, 2024 | Arthrosi Therapeutics |
| NCT06603142 | Phase 2/Phase 3 (Phase 3) | Apr 22, 2024 | Government of China |
| NCT05253833 | Phase 2 | Aug 12, 2022 | Arthrosi Therapeutics |
| NCT05119686 | Phase 2 | Nov 16, 2021 | Arthrosi Therapeutics |
| NCT04646889 | Phase 1 | Dec 31, 2020 | Arthrosi Therapeutics, IQVIA |
| NCT04508426 | Phase 1 | Jul 16, 2020 | Arthrosi Therapeutics, Celerion |
| NCT04155918 | Phase 2 | Dec 31, 2019 | Arthrosi Therapeutics, University of Otago |
| NCT04314986 | Phase 1 | Jun 28, 2019 | Arthrosi Therapeutics |
| NCT04347005 | Phase 1 | Jan 22, 2019 | Arthrosi Therapeutics |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arthrosi Therapeutics | For profit | 10 | 10 | 3 | 2019 |
| Celerion | For profit | 1 | 0 | 1 | 2020 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| IQVIA | For profit | 1 | 0 | 1 | 2020 |
| University of Otago | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1